Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20501611 | 1.00 | HPGD (0.37) | HPGDTP53ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL21805130 | 0.85 | KMT2A (0.43) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL21805829 | 0.80 | PLG (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL20501606 | 0.78 | TP53 (0.40) | HPGDTP53ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL14892803 | 0.78 | TP53 (0.40) | HPGDTP53ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL14892804 | 0.78 | TP53 (0.40) | HPGDTP53ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL11091753 | 0.76 | KMT2A (0.38) | HPGDKMT2ANPC1RAB9A | |
| SCHEMBL46300 | 0.74 | TP53 (0.42) | HPGDTP53ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL11516859 | 0.74 | EPHX1 (0.41) | HPGDSMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL14892272 | 0.74 | TP53 (0.42) | HPGDTP53ALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609888-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | LILLY CO ELI (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4596041-A2 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Organovo, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-110637015-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20220089575-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220054469-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3852737-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-113056264-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2021-06-29 | — | — | CN | disclosed |
| WO-2020061112-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-3609888-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| CN-110637015-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2019-12-31 | — | — | CN | disclosed |
| WO-2018170182-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054469-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | HPGD 563/4885TP53 3878/4885ALDH1A1 2205/4885 |
| US-20220089575-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | HPGD 563/4885TP53 3878/4885ALDH1A1 2205/4885 |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | HPGD 563/4885TP53 3878/4885ALDH1A1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.